These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18636334)

  • 1. Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes.
    Junyaprasert VB; Teeranachaideekul V; Supaperm T
    AAPS PharmSciTech; 2008; 9(3):851-9. PubMed ID: 18636334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride.
    Hasan AA
    Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine-loaded niosomes: characterization and in vitro release studies.
    Khazaeli P; Pardakhty A; Shoorabi H
    Drug Deliv; 2007 Oct; 14(7):447-52. PubMed ID: 17994362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorbitane Monostearate and Cholesterol based Niosomes for Oral Delivery of Telmisartan.
    Ahad A; Raish M; Al-Jenoobi FI; Al-Mohizea AM
    Curr Drug Deliv; 2018 Feb; 15(2):260-266. PubMed ID: 28521674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of formulation variables and excipient interaction on the production of niosomes.
    Sezgin-Bayindir Z; Yuksel N
    AAPS PharmSciTech; 2012 Sep; 13(3):826-35. PubMed ID: 22644706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preformulation characterization and identification of excipients for nevirapine loaded niosomes.
    Witika BA; Walker RB
    Pharmazie; 2021 Feb; 76(2):77-83. PubMed ID: 33714283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
    Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
    Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterisation of Span 65 niosomal formulations containing proteins.
    Haj-Ahmad RR; Elkordy AA; Chaw CS
    Curr Drug Deliv; 2015; 12(5):628-39. PubMed ID: 25963305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying the Taguchi method to optimize sumatriptan succinate niosomes as drug carriers for skin delivery.
    González-Rodríguez ML; Mouram I; Cózar-Bernal MJ; Villasmil S; Rabasco AM
    J Pharm Sci; 2012 Oct; 101(10):3845-63. PubMed ID: 22806266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of formulation compositions on niosomal preparations.
    Chaw CS; Kim KY
    Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemoglobin niosomes. I. Preparation, functional and physico-chemical properties, and stability].
    Moser P; Marchand-Arvier M; Labrude P; Handjani-Vila RM; Vigneron C
    Pharm Acta Helv; 1989; 64(7):192-202. PubMed ID: 2762361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus.
    Bendas ER; Abdullah H; El-Komy MH; Kassem MA
    Int J Pharm; 2013 Dec; 458(2):287-95. PubMed ID: 24184035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
    Mokhtar M; Sammour OA; Hammad MA; Megrab NA
    Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid.
    Junyaprasert VB; Singhsa P; Suksiriworapong J; Chantasart D
    Int J Pharm; 2012 Feb; 423(2):303-11. PubMed ID: 22155414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium dodecyl sulfate improved stability and transdermal delivery of salidroside-encapsulated niosomes via effects on zeta potential.
    Zhang Y; Jing Q; Hu H; He Z; Wu T; Guo T; Feng N
    Int J Pharm; 2020 Apr; 580():119183. PubMed ID: 32112930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proniosomes as drug carriers.
    Sankar V; Ruckmani K; Durga S; Jailani S
    Pak J Pharm Sci; 2010 Jan; 23(1):103-7. PubMed ID: 20067875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine.
    Shaikh KS; Chellampillai B; Pawar AP
    Drug Dev Ind Pharm; 2010 Aug; 36(8):946-53. PubMed ID: 20196642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium.
    Abd-Elbary A; El-laithy HM; Tadros MI
    Int J Pharm; 2008 Jun; 357(1-2):189-98. PubMed ID: 18339494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin.
    Manconi M; Sinico C; Valenti D; Lai F; Fadda AM
    Int J Pharm; 2006 Mar; 311(1-2):11-9. PubMed ID: 16439071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and characterization of ofloxacin niosomes.
    Ramalingam N; Natesan G; Dhandayuthapani B; Perumal P; Balasundaram J; Natesan S
    Pak J Pharm Sci; 2013 Nov; 26(6):1089-96. PubMed ID: 24191311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.